Journals / European Journal of Therapeutics / 2017 / Cilt: 23 - Sayı: 2

The frequency of hepatitis B virus reactivation in patients with bone marrow transplantation

Kemik iliği nakli yapılan hastalarda hepatit B virus reaktivasyon sıklığı

Pages
67–73
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, the risk of HBV reactivation is minimized, and a preventive approach should always be considered for patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: All patients with serologic evidence of a previous hepatitis B virus ( HBV )infection have the risk of reactivation.
📊
Key Findings & Data:The present study aimed to determine the prevalence of HBV infection/reactivation and to identify possible factors causing reactivation in patients who underwent bone marrow transplantation.Methods: In total, 442 patients who underwent allogeneic and autologous peripheral stem cell transplantation between April 2011 and December 2016 were included.
💡
Conclusion & Impact:Thus, the risk of HBV reactivation is minimized, and a preventive approach should always be considered for patients.
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: All patients with serologic evidence of a previous hepatitis B virus ( HBV )infection have the risk of reactivation. The present study aimed to determine the prevalence of HBV infection/reactivation and to identify possible factors causing reactivation in patients who underwent bone marrow transplantation.Methods: In total, 442 patients who underwent allogeneic and autologous peripheral stem cell transplantation between April 2011 and December 2016 were included. Hepatitis B virus serologies, chemotherapy regimens received, and antiviral treatments were retrospectively evaluated. Results: The number of HBsAg-positive patients was 36 (8.1%) and that of HBsAg-negative/anti-HBc-positive patients was 74 (16.7%); antiviral treatment was given to all patients. There was no HBV reactivation at the median follow-up of 21 months. Conclusion: All patients receiving immunosuppressive therapy should be screened for HBV infection and evaluated for the prophylactic treatment of HBV. Thus, the risk of HBV reactivation is minimized, and a preventive approach should always be considered for patients.

Özet

Amaç: Daha önce hepatitis B virüs (HBV) enfeksiyonu geçirdiğine dair serolojik kanıtı olan tüm hastalar; immunsupresif tedavi alacak olmaları halinde reaktivasyon riski ile karşı karşıyadırlar. Çalışmamızda; kemik iliği transplantasyonu yapılan hastalarda, HBV infeksiyon/reaktivasyon sıklığı ve reaktivasyona sebep olan olası etmenleri belirlemek amaçlandı.Yöntemler: Çalışmaya Nisan 2011 ve Aralık 2016 tarihleri arasında allojenik ve otolog periferik kök hücre transplantasyonu (PKHT) yapılan 442 hasta alındı. Hepatit B virüs serolojilerine, aldıkları kemoterapi rejimlerine ve antiviral tedavilere retrospektif olarak bakıldı. Bulgular: HBsAg pozitif hasta sayısı 36 (%8,1), HBsAg negatif/Anti-HBc pozitif hasta sayısı 74 (%16,7) olup, hastaların tamamına antiviral tedavi verildi. Medyan 21 aylık izlemde hiç reaktivasyon saptanmadı. Sonuç: İmmunsupresif tedavi alacak tüm hastalar, HBV açısından taranmalı, profilaktik tedavi açısından değerlendirilmelidir. Böylece HBV reaktivasyon riski en aza indirilerek, her zaman hastalara preventif yaklaşım içinde bulunulmalıdır.

🔖

Cite This Article

ŞAHİN, H. H., GÜLŞEN, M. T., PEHLİVAN, M., BALKAN, A., BALKAN, Y., BUDEYRİ, S., KIRIK, M. P., GÜNDEŞ, İ. (2022). The frequency of hepatitis B virus reactivation in patients with bone marrow transplantation. European Journal of Therapeutics, Cilt: 23 - Sayı: 2, 67–73. https://ajindex.com/articles/512353

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015
  2. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61: 703-11. [CrossRef] 3. Tosun S. Viral hepatitlerin ülkemizdeki değişen epidemiyolojisi. Ankem Derg 2013; 27: 128-34
  3. Tosun S. Türkiye'de viral hepatit B epidemiyolojisi: yayınların meta analizi. In: Tabak F, Tosun S, editors. Viral Hepatit 2013. Ankara: Viral Hepatitle Savaşım Derneği, 2013: 27-80
  4. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-44. [CrossRef] 6. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28. [CrossRef] 7. Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA 2015; 313: 1617-8. [CrossRef] 8. Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164: 30-40. [CrossRef] 9. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49(5 Suppl): S156-65. [CrossRef] 10. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-8. [CrossRef] 11. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85. [CrossRef] 12. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61. [CrossRef] 13. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20
  5. Lok AS, McMahon BJ. Chronic hepa